Status:

COMPLETED

ROSA Total Knee Post Market Study EMEA

Lead Sponsor:

Zimmer Biomet

Conditions:

Knee Pain

Chronic Osteoarthritis

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This is a prospective, multicenter clinical study designed to facilitate the collection and evaluation of surgical workflow efficiency, patient pain and function outcome and adverse events data. This ...

Detailed Description

The main purpose of this study is to collect and compare clinical outcomes data using the commercially available ROSA Total Knee robotic instrumentation and conventional instrumentation. This will be ...

Eligibility Criteria

Inclusion

  • Inclusion/Exclusion criteria Inclusion criteria:
  • Patient is a minimum of 18 years of age
  • Independent of study participation, patient is a candidate for commercially available Persona, NexGen, or Vanguard knee components implanted in accordance with product labeling
  • Patient has participated in this study-related Informed Consent Process
  • Patient is willing and able to provide written Informed Consent by signing and dating the EC approved Informed Consent form
  • Patient is willing and able to complete scheduled study procedures and follow-up evaluations
  • Exclusion criteria:
  • Patient is currently participating in any other surgical intervention studies or pain management studies
  • Patient has underwent contralateral UKA or TKA within the last 18 months
  • Hip pathology with significant bone loss (e.g. avascular necrosis of the femoral head with collapse, severe dysplasia of the femoral head or the acetabulum)
  • Hip pathology severely limiting range of motion (e.g. arthrodesis, severe contractures, chronic severe dislocation)
  • Patient is pregnant or considered a member of a protected population (e.g., prisoner, mentally incompetent, etc.)
  • Patient has previously received partial or total knee arthroplasty for the ipsilateral knee

Exclusion

    Key Trial Info

    Start Date :

    December 15 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 22 2025

    Estimated Enrollment :

    252 Patients enrolled

    Trial Details

    Trial ID

    NCT04338893

    Start Date

    December 15 2020

    End Date

    August 22 2025

    Last Update

    September 17 2025

    Active Locations (6)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (6 locations)

    1

    Cliniques Universitaires Saint-Luc

    Brussels, Belgium

    2

    Herzogin Elisabeth Hospital

    Braunschweig, Germany

    3

    Evangelisches Waldkrankenhaus Spandau

    Spandau, Germany

    4

    The Research Fund of Hadassah Medical Organization

    Jerusalem, Israel